EMILIO AGUINALDO COLLEGE

School of Nursing

DRUG STUDY

NAME: Harper L. Olpindo PATIENT NAME: B.M AGE: 62 years old DATE: 09/19/19
STUDENT #: 17-3-01217 DIAGNOSIS: CKD Stage 5 secondary to DM & HPN GENDER: Male

Generic Name: Classification and Indication: Mechanism of Action: Contraindications: Side Effects: Nursing Considerations
Category:
Candersartan Patient with Inhibits vasoconstrictive Contraindicated in Dizziness  If hypotension occurs
impaired renal action of angiotensin II by patients hypertensive after a dose of
Brand Name: Fatigue
function, administer blocking angiotensin II to drug or it’s candesartan, place
A. Chemical: Headache
Atacand under close medical receptor on the surface of component, in children patient in the supine
Angiostension II supervision and vascular smooth muscle with GFR of less than Chest Pain position, and if
Dosage:
Receptor consider a lower and other tissue cells. 30 mL/min/1.73 m2, needed, give an I.V.
90 mg Antagonists starting dose. and in children younger Abdominal Pain infusion of NSS.
than age 1. Diarrhea  Carefully monitor
Route: B. Therapeutic:
elderly patients and
Nausea & Vomiting
PO Antihypertensives those with renal
Adverse Reactions: disease for
Frequency:
therapeutic response
Pharyngitis
OD AM and adverse reaction.
Rhinitis
Sinusitis
Peripheral Edema
Arthralgia
 EMILIO AGUINALDO COLLEGE
School of Nursing

DRUG STUDY

NAME: Harper L. Olpindo PATIENT NAME: B.M AGE: 62 years old DATE: 09/19/19
STUDENT #: 17-3-01217 DIAGNOSIS: CKD Stage 5 secondary to DM & HPN GENDER: Male

Generic Name: Classification and Indication: Mechanism of Action Contraindications: Side Effects: Nursing Considerations
Category:
Carvedilol In patients with Nonselective beta blocker Contraindicated in Dizziness  Mild hepatocellular
pulse rate below 55 with alpha blocking patients with bronchial injury may occur
Brand Name: Fatigue
beats/minute, activity asthma or related during therapy. At
B. Chemical:
Coreg reduce dosage bronchospastic Pain first sign of hepatic
Alpha-nonselective conditions, second-or- dysfunction, perform
Dosage: Headache
beta blockers third degree AV block, tests for hepatic
25 mg sick sinus syndrome, Vertigo injury or jaundice: if
B. Therapeutic:
severe brachycardia, or present, STOP DRUG.
Route: Fever
Anti-hypertensives severe hepatic  Monitor patient with
PO impairment Abnormal vision HF for worsened
Pharmacokinetics:
condition, renal
Frequency: Adverse Reactions:
Onset: Rapid dysfunction, or fluid
OD PM Stroke retention: diuretics
Peak: 1-2hr
may need to be
Pharmacokinetics: AV Block
Duration: 7 – 10 hr increase.
Onset: Rapid Bradycardia  Monitor diabetic
Half-life:
Peak: 1-2hr patient only.
Immediate-Release Thrombocytopenia
 Monitor elderly
Duration: 7 – 10 hr Lung Edema patient carefully.
Half-life: Immediate- Hyper/Hypoglycemia
Release
 EMILIO AGUINALDO COLLEGE
School of Nursing

DRUG STUDY

NAME: Harper L. Olpindo PATIENT NAME: B.M AGE: 62 years old DATE: 09/19/19
STUDENT #: 17-3-01217 DIAGNOSIS: CKD Stage 5 secondary to DM & HPN GENDER: Male

Generic Name: Classification and Indication: Mechanism of Action: Contraindications: Side Effects: Nursing Considerations
Category:
Sevelamer To control Inhibits intestinal Contraindicated in Headache  Monitor calcium,
phosphorus level in phosphate absorption and patients hypersensitive bicarbonate, and
Brand Name: Fever
chronic kidney decreases phosphorus to drug or its chloride level.
C. Chemical:
Renvela disease patients on levels. composition and in Pain
Polymeric dialysis. those with
Dosage: Diarrhea
Phosphate Binders hypophosphatemia or
800 MG bowel obstruction. Vomiting & Nausea
Route:
B. Therapeutic:
PO Adverse Reactions:
Hypophosphatemics
Frequency: Hypertension
OD Hypercalcemia
Dyspepsia
Pruritus
 EMILIO AGUINALDO COLLEGE
School of Nursing

DRUG STUDY

NAME: Harper L. Olpindo PATIENT NAME: B.M AGE: 62 years old DATE: 09/19/19
STUDENT #: 17-3-01217 DIAGNOSIS: CKD Stage 5 secondary to DM & HPN GENDER: Male

Generic Name: Classification and Indication: Mechanism of Action: Contraindications: Side Effects: Nursing Considerations
Category:
Epoetin Alfa Anemia caused by Mimics effect of Contraindicated in  Dizziness  Monitor BP before
Chronic Renal erythropoietin. Functions patients hypersensitive  Depression therapy.
Brand Name:
Disease. as a growth factor and as to products derived  Headache  Monitor Hb level
D. Chemical:
Eprex a differentiating factor from mammal cells or  Increase clotting twice weekly until it
Recombinant enhancing RBC albumin, in those with of AV Graft stabilizes in the target
Dosage:  Gi Discomforts
Human production. uncontrolled HPN or and maintenance
4000 u Erythropoietins pure RBC aplasia that dose is established.
begins after treatment Adverse Reactions:  Monitor blood
Route: B. Therapeutic:
with epoetin, and in counts.
Seizures
SC Colony Stimulating patients receiving  Patient may need
Factors myelosuppressive Hyperglycemia additional heparin to
Frequency:
chemotherapy when prevent clotting
Pharmacokinetics: Hypokalemia
3X/Week the outcome is cure. during dialysis
Onset: Immediate Muscle Spasm treatments.
Peak: Immediate
Bone Pain
Duration: Unknown
Half-life: 4 to 13
hours
 EMILIO AGUINALDO COLLEGE
School of Nursing

DRUG STUDY

NAME: Harper L. Olpindo PATIENT NAME: B.M AGE: 62 years old DATE: 09/19/19
STUDENT #: 17-3-01217 DIAGNOSIS: CKD Stage 5 secondary to DM & HPN GENDER: Male

Generic Name: Classification and Indication: Mechanism of Action: Contraindications: Side Effects: Nursing Considerations
Category:
Clopidrogel bisulfate To reduce Inhibits the binding of Contraindicated in Confusions  Instruct patient to
thrombotic events in adenosine diphosphate patient hyper sensitive Abdominal pain notify prescriber if
Brand Name: Diarrhea
patients with (ADP) to its platelet to drug or its unusual bleeding or
E. Chemical:
Plavix atherosclerosis receptor, impeding ADP- components. bruising occurs.
Platelet documented by mediated activation and Adverse Reactions:  Inform patient that
Dosage:
aggregation recent stroke, MI or subsequent platelet drug may be taken
75 mg inhibitors peripheral arterial aggregation, and Rash without regard for
disease. irreversibly modifies the Hypotension meals
Route: B. Therapeutic:
platelet ADP receptor. UTI  Advise patient that it
PO Antiplatelet drugs Bronchospasm may take longer than
Hemorrhage usual to stop
Frequency:
Bruising bleeding. Tell him to
OD refrain from activities
in which trauma and
bleeding may occur,
and encourage him to
wear a seat belt when
in a car.